EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients

Victor Poon iD, Dhruvitkumar Sutaria iD, Rodney Prell iD, Wendy Halpern iD, Lisa Wong iD, Adam Harris, Justin Wilkins iD, Kenta Yoshida iD, Rucha Sane iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70298 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Victor Poon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Long QT Syndrome, Neoplasms, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

QTc prolongation has been associated with torsades de pointes (TdP) and also with other cardiac diseases. We investigated the effect of ipatasertib, a selective serine/threonine kinase (AKT, protein kinase B) inhibitor, on preclinical models of QTc prolongation as well as across two clinical studies. Preclinical in vitro studies suggested that ipatasertib and its metabolite, M1, were unlikely to inhibit human Ether‐à‐go‐go‐Related Gene (hERG) channels at the clinically relevant dose. However, clinical evaluation of ipatasertib and its metabolite in the first‐in‐human study PAM4743g suggested a mild prolongation of the QTc interval, but the effect was delayed, where the maximum change from baseline QTc seemed to occur 2–4 h after time to maximum drug exposure (T max ). QTc prolongation was further evaluated in a second Phase 1b study, GP42658, with pretreatment QTc measurement for baseline correction and intensive post‐baseline QTcF measurements at steady state. The results showed a delayed effect, where peak ΔQTcF occurred 2–4 h after T max with a mean of 10.9 ms and an upper 95% CI of 19.1 ms. Although a delayed effect was observed, the overall magnitude of the QTc effect was not large, and taken together, ipatasertib may not pose a substantial proarrhythmic risk (i.e., mean increase of > 20 ms) at the intended therapeutic dose of 400 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeNeoplasmsProtein Kinase InhibitorsPyrimidinesAdultAgedAnimalsFemaleHumansMaleMiddle AgedDrug Evaluation, PreclinicalElectrocardiographyERG1 Potassium ChannelTorsades de PointesPiperazines

Stichwörter der Autor:innen

C‐QTECGQT/QTc prolongationcancerhERGhysteresisipatasertib

Substanzen

ERG1 Potassium ChannelipatasertibProtein Kinase InhibitorsPyrimidinesPiperazines

Autor:innen und Institutionen

  • Genentech, South San Francisco, California, USA.
  • Occams, Amstelveen, the Netherlands.

ORCID-Profile: Victor Poon, Dhruvitkumar Sutaria, Rodney Prell, Wendy Halpern, Lisa Wong, Justin Wilkins, Kenta Yoshida, Rucha Sane

Zitieren

APA

Poon, V., Sutaria, D., Prell, R., Halpern, W., Wong, L., Harris, A., Wilkins, J., Yoshida, K., & Sane, R. (2025). Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients. Clinical and Translational Science. https://doi.org/10.1111/cts.70298

Vancouver

Poon V, Sutaria D, Prell R, Halpern W, Wong L, Harris A, et al. Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients. Clinical and Translational Science. 2025. doi:10.1111/cts.70298

BibTeX
@article{Poon2025,
  author = {Poon, Victor and Sutaria, Dhruvitkumar and Prell, Rodney and Halpern, Wendy and Wong, Lisa and Harris, Adam and Wilkins, Justin and Yoshida, Kenta and Sane, Rucha},
  title = {Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70298}
}
Kostenlos starten →